Institutional shares held 43.4 Million
124K calls
122K puts
Total value of holdings $12.9B
$36.7M calls
$36.3M puts
Market Cap $13.5B
45,516,300 Shares Out.
Institutional ownership 95.33%
# of Institutions 734


Latest Institutional Activity in UTHR

Top Purchases

Q2 2025
Robeco Institutional Asset Management B.V. Shares Held: 235K ($69.8M)
Q2 2025
Signal Advisors Wealth, LLC Shares Held: 5.34K ($1.59M)
Q2 2025
Augustine Asset Management Inc Shares Held: 5.28K ($1.57M)
Q2 2025
State Of Alaska, Department Of Revenue Shares Held: 19.5K ($5.81M)
Q2 2025
Wealth Enhancement Advisory Services, LLC Shares Held: 6.08K ($1.81M)

Top Sells

Q2 2025
Assenagon Asset Management S.A. Shares Held: 34K ($10.1M)
Q2 2025
Livforsakringsbolaget Skandia, Omsesidigt Shares Held: 400 ($119K)
Q2 2025
Wedge Capital Management L L P Shares Held: 95.8K ($28.5M)
Q2 2025
Nepsis Inc. Shares Held: 47.8K ($14.2M)
Q2 2025
Ruffer LLP Shares Held: 10.8K ($3.2M)

About UTHR

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.


Insider Transactions at UTHR

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
954K Shares
From 13 Insiders
Exercise of conversion of derivative security 725K shares
Bona fide gift 230K shares
Sell / Disposition
962K Shares
From 17 Insiders
Exercise of conversion of derivative security 2.3K shares
Open market or private sale 653K shares
Sale (or disposition) back to the issuer 75.9K shares
Bona fide gift 232K shares

Track Institutional and Insider Activities on UTHR

Follow UNITED THERAPEUTICS Corp and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells UTHR shares.

Notify only if

Insider Trading

Get notified when an United Therapeutics Corp insider buys or sells UTHR shares.

Notify only if

News

Receive news related to UNITED THERAPEUTICS Corp

Track Activities on UTHR